 Overactive bladder OAB syndrome is characterized by the symptom complex of urinary urgency, usually with associated frequency and nocturia, with or without urgency urinary incontinence in the absence of infection or other pathology. OAB affects approximately 31 of women over the age of 65. Vaginal estrogen, a well-documented treatment for OAB in hypoestrogenic women, has been shown to improve symptoms of frequency, urgency and urgency urinary incontinence UUI. Several theories have been proposed to explain the mechanism underlying estrogens effect on lower urinary tract symptoms LUTS. The investigators propose that estrogen treatment influences bacterial communities microbiomes in the vagina and bladder and alters urothelial and vaginal AMPs thereby improving OAB symptoms in hypoestrogenic women. 